Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Light-Activated ‘Smart Bomb’ Advances Breast Cancer Treatment

By HospiMedica International staff writers
Posted on 13 Feb 2025

Photodynamic therapy (PDT) has been used for many years to treat certain types of skin and bladder cancers. More...

The treatment works by introducing light-sensitive chemicals into the patient’s body, which accumulate in cancer cells. When exposed to light, these chemicals are activated and destroy the cancerous cells. The light prompts the chemicals to produce highly reactive oxygen molecules, which act like tiny biochemical firecrackers, breaking down cancer cells from within while leaving healthy cells unharmed. While PDT is an effective treatment, it has several limitations, including prolonged light sensitivity, poor tissue penetration, and off-target toxicity. These issues can hinder complete tumor destruction and may contribute to cancer recurrence. Researchers have now developed new light-sensitive chemicals that promise to significantly enhance the treatment of aggressive cancers with fewer side effects. In mouse studies, this new therapy completely eliminated metastatic breast cancer tumors. These innovative chemicals, known as cyanine-carborane salts, and their potential in advancing cancer treatment, are discussed in a recent article published in Angewandte Chemie.

Current FDA-approved PDT chemicals tend to remain in the body for extended periods. Following treatment, patients must avoid light for two to three months, as even low levels of light can cause blisters and burns. In contrast, a multidisciplinary team of scientists from the University of California, Riverside (Riverside, CA, USA) and Michigan State University (MSU, East Lansing, MI, USA) discovered that cyanine-carborane salts are eliminated from the body more quickly, staying only in the cancer cells that require treatment. Unlike traditional PDT agents, the salts take advantage of a natural weakness in cancer cells. They are absorbed by proteins called OATPs, which are overexpressed in tumor cells. This mechanism allows for precise targeting without the need for costly additional chemicals that are typically used in PDT to direct the therapy to the cancer cells.

Traditional PDT is also limited when it comes to treating deep-seated tumors because it relies on light wavelengths that only penetrate a few millimeters into the body. However, once inside cancer cells, cyanine-carborane salts can be activated by near-infrared light, which can penetrate more deeply into tissues. This could significantly broaden the range of cancers that can be treated. Given the promising results, researchers are encouraged to continue their work and explore additional cancer therapies that could benefit from these salts. It may even be possible to modify the salts so they can be activated by energy sources other than light, allowing for deeper penetration into the body.

“Our work offers a targeted, safe, and cost-effective treatment for aggressive breast cancers with limited treatment options,” said Amir Roshanzadeh, paper first author and MSU cell & molecular biology graduate student. “It also opens the door to breakthroughs in other approaches for cancer therapy and targeted drug delivery.”


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Surgical System
Stealth AXiS
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.